The DOI matches its Crossref record.
Teratogenicity of Antiepileptic Drug Combinations with Special Emphasis on Epoxidation (of Carbamazepine)
Abstract
Summary: A higher rate of congenital anomalies has been found after prenatal exposure to some combinations of antiepileptic drugs than to the separate drugs. In an earlier study a rate of 58% congenital anomalies was found among infants exposed to carbamazepine plus phenobarbitone plus valproate. In this study an attempt was made to determine whether this specific combination of drugs has teratogenic activity due to metabolic interaction. The epidemiological data were analyzed further. The high rate of congenital anomalies after prenatal exposure to this combination could not be explained by the effects of one or two of these drugs only, nor by additional exposure to phenytoin. Assuming that metabolic interaction in the arene oxide pathway resulting in accumulation of epoxide intermediates of antiepileptic drugs could be responsible for teratogenesis, the ratio of carbamazepine to carbamazepine‐10,11‐epoxide concentrations in serum was determined in adult patients with epilepsy who were treated with carbamazepine only and with different combinations of phenobarbitone, valproate, and/or phenytoin. For carbamazepine monotherapy the mean ratio was 8.19. For all combinations lower ratios were found, indicating accumulation of carbamazepine‐10,11‐epoxide. The combination of carbamazepine, phenobarbitone, valproate, and phenytoin showed the lowest ratio (1.94), followed by carbamazepine, valproate, and phenytoin and by carbamazepine, phenobarbitone, and valproate (2.81 and 3.18, respectively). These results give rise to the question of whether the combination of carbamazepine, phenobarbitone, valproate, and/or phenytoin has teratogenic activity by accumulation of carbamazepine‐10,11‐epoxide or other epoxide intermediates, and stress the need to take metabolic interactions into account when investigating the teratogenic activity of antiepileptic drugs. RESUMEN: La exposición prenatal a algunas combinaciones de drogas antiepilépticas ha producido un índice más elevado de anomalias congénitas que si se administran separadamente. En un estudio previo se encontró un indice de un 58% de anomalias congénitas en niños expuestos a carbamazepina + fenobarbital + valproate En este estudio se intenta determinar si esta combinación específica de medicaciones tiene actividad teratogenética debida a interacciones metabólicas. La información epidemiológica se analiza con mas detalle. El elevado índice de anomalias congénitas tras la exposición prenatal a esta combinación no es posible explicaria por los efectos de una o dos drogas solamente, ni por la administración adicional de fenitoina. Aceptando que la inter‐acción metabólica en la via arene‐óxido, de la que surje un acúmulo de epóxidos intermediarios de las drogas antiepilépticas, podría ser responsable de la teratogénesis se ha determinado la relación de concentraciones en suero de carbamazepina/carbamazepina‐10, 11‐epóxido. Esta determinacyón se realizó en epilépticos adultos que habían sido tratados con carbamazepina solo o combinada con fenobarbital, valproato y/o fenitoina. El cociente medio para la carbamazepina fué 8.19. Para todas las combinaciones se encontraron relaciones más bajas, lo que indica un acúmulo de carbamazepina‐10, 11‐epóxido. La combinación carbamazepina + fenobarbital + valproato + fenitoina mostró la relación más baja (1.94), seguida de carbamazepina + valproato + fenitoina y carbamazepina + fenobarbital + valproato (2.81 y 3.18 respectivamente). Estos resultados plantean la posibilidad de si la combinación carbamazepina + fenobarbital + valproato + fenitoina tiene actividad teratogénica por acúmulo de carbamazepina‐10, 11‐epóxido o por otros intermediarios epóxidos. También resalta la necesidad de tener presentes las interacciones metabólicas cuando se investiga la capacidad teratogéa de las drogas antiepilécas. ZUSAMMENFASSUNG: Nach pränataler Exposition gegenüber Kombinationen von Antiepileptika wird eine höhere Rate kongenitaler Anomalien gefunden als bei Exposition gegenüber einzelnen Medikamenten. In einer früheren Untersuchung wurden 58% kongenitaler Anomalien bei Kindern gefunden, die einer Kombination von Carbamazepin, Phenobarbital und Valproat ausgesetzt waren. In dieser Untersuchung wird der Versuch gemacht, festzustellen, ob diese spezifische Kombination von Medikamenten eine teratogene Aktivität aufgrund metabolischer Interaktionen besitzt. Die epidemiologischen Daten wurden weiter analysiert. Der hohe Prozentsatz kongenitaler Anomalien nach pränataler Einwirkung dieser Medikamentenkombination konnte nicht als Wirkung von einem oder von zwei dieser Medikamente Oder gar duch eine zusätzliche Exposition gegenüber Phenytoin erklärt werden. In der Annahme, daß metabolische Interaktionen bei der Oxydation zur Anhäufung von Epoxyd‐Zwischenprodukten antiepileptischer Medikamente führt, die teratogen wirken, wurde das Verhältnis von Carbamazepin zu Carbamazepm‐10, 11‐Epoxyd im Serum von Erwachsenen mit Epilepsie untersucht, die mit Carbamazepin alleine und mit verschiedenen Kombinationen wie Phenobarbital, Valproat und/oder Phenytoin behandelt wurden. Für die Carbamazepin‐Monotherapie betrugt das mittlere Verhältnis 8, 19. Für alle Kombinationen wurden niedrigere Quotienten gefunden, die für eine Akkumulation von Carbamazepin‐10, 11‐Epoxyd sprechen. Die Kombination von Carbamazepin, Phenobarbital, Valproat und Phenytoin zeigte den niedrigsten Quotienten (1,94); dann folgten Carbamazepin, Valproat und Phenytoin, schließich Carbamazepin, Phenobarbital und Valproat (2,81, bzw. 3,18). Diese Ergebnisse lassen die Frage entstehen, ob die Kombination von Carbamazepin, Phenobarbital, Valproat und/oder Phenytoin durch Anhäufung von Carbamazepin‐10, 11‐Epoxyd oder andere Epoxyd‐Intermediär‐stoffe teratogen wirken. Sie betonten die Notwendigkeit, metabolische Interaktionen in Betracht zu Ziehen, wenn man die teratogene Aktivität antiepileptischer Medikamente untersucht.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Perucca, E. (2002) · CNS Drugs · doi:10.2165/00023210-200216100-00004 · Cited by 690
The Teratogenicity of Anticonvulsant Drugs
Holmes, L. B., Harvey, E. A., Coull, B. A., Huntington, K. B., Khoshbin, S., Hayes, A. M., & Ryan, L. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441504 · Cited by 655
A clinical study of 57 children with fetal anticonvulsant syndromes
Moore, S. J., Turnpenny, P., Quinn, A., Glover, S., Lloyd, D. J., Montgomery, T., & Dean, J. C. S. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.7.489 · Cited by 562
Pattern of Malformations in the Children of Women Treated with Carbamazepine during Pregnancy
Jones, K. L., Lacro, R. V., Johnson, K. A., & Adams, J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906223202505 · Cited by 447
Role of oxidative stress in epileptic seizures
Shin, E.-J., Jeong, J. H., Chung, Y. H., Kim, W.-K., Ko, K.-H., Bach, J.-H., Hong, J.-S., Yoneda, Y., & Kim, H.-C. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.03.025 · Cited by 422
Metadata
- Authors
- Lindhout, D., Höppener, R. J. E. A., & Meinardi, H.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 1984-02
- Volume
- 25
- Issue
- 1
- Pages
- 77-83
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2127345802
- Cited by
- 208
- References
- 0
- FWCI
- 11.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Teratogenicity of Antiepileptic Drug Combinations with Special Emphasis on Epoxidation (of Carbamazepine). https://app.cochat.ai/papers/10.1111/j.1528-1157.1984.tb04158.x
- The paper
- Lindhout, D., Höppener, R. J. E. A., & Meinardi, H. (1984). Teratogenicity of Antiepileptic Drug Combinations with Special Emphasis on Epoxidation (of Carbamazepine). Epilepsia. https://doi.org/10.1111/j.1528-1157.1984.tb04158.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.